Showing results (31-40 of 53) with videos related to

Sort By:
Pageof 6
Scientific Reports|May 2, 2025
A model workflow for microfluidic enrichment and genetic analysis of circulating melanoma cellsCristina Poggiana, Alessandro Francesco Piazza, Cristina Catoni, et al.
Journal of the American Academy of Dermatology|November 17, 2016
Mitotic rate correlates with sentinel lymph node status and outcome in cutaneous melanoma greater than 1 millimeter in thickness: A multi-institutional study of 1524 casesMario Mandalà, Francesca Galli, Laura Cattaneo, et al.
Journal of Neuro-Oncology|February 18, 2014
Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastasesPaola Queirolo, Francesco Spagnolo, Paolo Antonio Ascierto, et al.
European Journal of Cancer (Oxford, England : 1990)|October 9, 2013
Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanomaMichele Del Vecchio, Lorenza Di Guardo, Paolo A Ascierto, et al.
Journal for Immunotherapy of Cancer|November 18, 2020
Body mass index (BMI) and outcome of metastatic melanoma patients receiving targeted therapy and immunotherapy: a multicenter international retrospective studyPiotr Rutkowski, Alice Indini, Matilde De Luca, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 28, 2019
Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 TrialCeleste Lebbé, Nicolas Meyer, Laurent Mortier, et al.
Journal of Translational Medicine|June 3, 2014
Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohortPaolo A Ascierto, Ester Simeone, Vanna Chiarion Sileni, et al.
Journal of Experimental & Clinical Cancer Research : CR|April 9, 2014
Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programmeVanna Chiarion Sileni, Jacopo Pigozzo, Paolo Antonio Ascierto, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 21, 2026
MONETTE: A Randomized Phase II Study of Ceralasertib plus Durvalumab or Ceralasertib Monotherapy in Patients with Advanced Melanoma Resistant to PD-(L)1 InhibitionMax Schlaak, Carolina Cimminiello, Jacopo Pigozzo, et al.
Pageof 6